Search

A recent report from Emory University discusses the use of milrinone in patients with hypoplastic left heart syndrome before the Norwood procedure. The study found that milrinone was well tolerated, decreased lactate levels, and did not lead to significant hypotension or worsening of excess pulmonary blood flow. This research provides valuable insights into the treatment of hypoplastic left heart syndrome in newborns. [Extracted from the article]

A recent study conducted at the Onassis Cardiac Surgery Center in Athens, Greece, compared the effectiveness of intravenous levosimendan and inhalational milrinone in managing pulmonary hypertension (PH) during adult cardiac surgery. The study found that both levosimendan and milrinone were effective in reducing pulmonary artery pressure and preventing the exacerbation of PH and right ventricular failure. However, levosimendan provided longer and greater pulmonary vasodilation compared to milrinone. These findings suggest that levosimendan may be a safe and beneficial therapeutic option for patients with preexisting PH undergoing cardiac surgery. [Extracted from the article]

A study conducted by researchers at Kwame Nkrumah University of Science and Technology in Ghana focused on the management of obstructed total anomalous pulmonary venous connection (OTAPVC) in patients with high pulmonary arterial pressure (PAP). The study compared the outcomes of patients who received milrinone alone versus those who received a combination of milrinone and inhaled nitric oxide (INO) during the post-operative period. The results showed that the combination therapy had better outcomes, with shorter ventilation time, length of stay in the cardiac care unit (CCU) and hospital, and lower rates of complications. The study concluded that managing severe pulmonary arterial hypertension (PAH) with a combination of milrinone and INO is more effective than milrinone alone. [Extracted from the article]

A new study from the Universidad de La Sabana compares the effectiveness of two medications, levosimendan and milrinone, in treating various cardiovascular conditions. The research suggests that levosimendan may be a non-inferior alternative to dobutamine and superior to milrinone in treating low cardiac output syndrome following cardiac surgery. Levosimendan has also been linked to lower mortality rates in cases of septic shock, while the efficacy of milrinone remains inconclusive. However, further research is needed to fully understand the impact of levosimendan on hemodynamic outcomes and other factors in patients with cardiogenic shock and septic shock. [Extracted from the article]

A recent study conducted at Advocate Children's Hospital in Oak Lawn, Illinois, aimed to investigate the effects of vasoactive medications on cardiovascular parameters in pediatric patients with decreased ejection fraction. The study utilized a physics-based computer simulator to analyze the impact of different medications and their combinations on cardiac output and systemic venous saturation. The results showed that dobutamine and milrinone, when used alone or in combination with other vasoactive agents, significantly increased cardiac output and systemic venous saturation. However, the administration of epinephrine and norepinephrine alone decreased these hemodynamic parameters. The study concluded that milrinone and dobutamine were the only medications that improved systemic oxygen delivery, but caution should be exercised due to the potential negative effects on afterload. [Extracted from the article]

A recent study conducted at the University of Chicago Medical Center has found that hemodynamic measurements, specifically the aortic pulsatility index (API) and cardiac power output (CPO), can be used to assess the risk and prognosis of patients with cardiogenic shock (CS). The study involved 224 patients with stage C CS who underwent a milrinone drug study to evaluate their inotropic response. The results showed that patients with low API and CPO had a higher incidence of adverse outcomes, such as the need for left ventricular assist device (LVAD), orthotopic heart transplantation (OHT), or death, compared to those with higher API and CPO values. The findings suggest that dynamic assessment of hemodynamics using API and CPO can improve risk stratification and guide treatment decisions for patients with CS. [Extracted from the article]

The article reports on a case involving an 11-year-old with traumatic subarachnoid hemorrhage and refractory cerebral vasospasm treated with dual intraventricular vasodilators. Topics include the use of combined intraventricular vasodilators to address resistant cerebral vasospasm; the efficacy of IVT nicardipine and IV milrinone in reducing transcranial Doppler mean velocities; and the potential benefits of dual vasodilator therapy in improving outcomes for pediatric patients.

A recent study conducted by the Department of Anesthesiology explored the use of milrinone as a potential alternative to nitroglycerin in reducing central venous pressure (CVP) during laparoscopic hepatectomy (LH). The study found that milrinone was effective in controlling low CVP and resulted in lower blood loss during the surgery compared to nitroglycerin. Additionally, the milrinone group exhibited better surgical field grading, higher cardiac index and cardiac output, and differences in fluid administration and norepinephrine dosage. The findings suggest that milrinone infusion can help maintain hemodynamic stability and reduce blood loss during LH. [Extracted from the article]

A recent study conducted by researchers at Ain Shams University compared the effectiveness of two medications, levosimendan and milrinone, in improving pulmonary hypertension after cardiac surgery. The study found that levosimendan led to a more significant increase in postoperative TAPSE (tricuspid annular plane systolic excursion), while milrinone resulted in a greater decrease in pulmonary artery pressure (PAP) and right ventricular systolic pressure (RVSP). Additionally, the milrinone group experienced an increase in postoperative AST/ALT levels. The study did not find any statistically significant differences between the two groups in terms of demographic data, kidney function, acid-base data, or weaning from ventilators. [Extracted from the article]

A recent study conducted in Bogota, Colombia, examined the effects of milrinone on microcirculation and endothelial glycocalyx in children with septic shock. The study found that children who received milrinone infusions maintained functional capillary density and capillary recruitment capacity, and had less endothelial glycocalyx degradation compared to those who did not receive milrinone. These changes were more significant in children under two years of age. The findings suggest that milrinone may have beneficial effects on microcirculation in children with septic shock. [Extracted from the article]

A scoping review conducted by researchers at the Icahn School of Medicine at Mount Sinai explored the use of novel inhaled vasodilators, milrinone and levosimendan, as alternatives to conventional inhaled therapies for pulmonary hypertension (PH) in cardiac surgery. The review included 17 studies with a total of 969 patients and found that milrinone and levosimendan showed potential benefits such as ease of weaning from cardiopulmonary bypass and reduction in ventricular dysfunction. However, the review also noted that high-quality data are limited and more consistent outcome measures are needed to validate the effectiveness of these agents. The study was registered with the Open Science Framework. [Extracted from the article]

A study conducted at the U.N. Mehta Institute of Cardiology and Research Centre compared the effects of inhaled milrinone (iMiL) and intravenous milrinone (IVMil) on patients with severe mitral stenosis (MS) and pulmonary arterial hypertension (PAH) undergoing mitral valve replacement surgery. The study found that iMiL led to a reduction in pulmonary artery pressure and pulmonary vascular resistance compared to IVMil. Patients in the iMiL group also showed improvements in right ventricular and systemic hemodynamics, as well as a lower incidence of acute right ventricular failure. The study concluded that intraoperative inhalational milrinone is superior to intravenous milrinone in preventing post-operative morbidity and mortality. [Extracted from the article]

A recent study conducted at the National University Heart Center in Singapore explored the use of adjunctive cardioprotective therapy during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). The study involved 22 patients who were randomized into two groups: an active group that received a combination therapy of Milrinone and Esmolol, and a placebo group that received saline infusion. The results showed that patients in the placebo group had higher improvement in infarct size compared to those in the active group. Further research is needed to assess the results of scar regression. [Extracted from the article]

A recent study conducted by researchers at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, aimed to compare the effectiveness of different interventions for treating transitional circulatory instability (TCI) in preterm neonates. The study analyzed data from 15 randomized controlled trials and used a Bayesian random effects network meta-analysis. The results suggested that epinephrine may be a suitable first-line drug for preterm neonates with TCI, although the certainty of the evidence was very low. The researchers recommended future trials with objective criteria to define TCI. [Extracted from the article]

A new study conducted at Sir Ganga Ram Hospital in New Delhi, India compared the effects of two drugs, levosimendan and milrinone, in managing low cardiac output after the arterial switch operation in infants weighing up to 3 kg. The study found that levosimendan was as safe and effective as milrinone in treating low cardiac output syndrome. Additionally, levosimendan was found to be renal protective compared to milrinone. The study provides valuable insights into the use of these drugs in neonatal cardiac care. [Extracted from the article]

Researchers from Ocean University of China have conducted a study on the optimization of anti-heart failure medication milrinone. The study focuses on the design and assembly of a ternary salt cocrystal of milrinone using gallic acid and 3,5-dinitrobenzoic acid. The researchers found that the ternary salt cocrystal significantly improved the solubility and permeability of milrinone compared to the parent medicine. This research provides a new cocrystalline model for milrinone and demonstrates the potential of ternary salt cocrystals in modifying the properties of anti-heart failure medicines. [Extracted from the article]

A study conducted at Hamad Medical Corporation in Doha, Qatar, examined the management of chylothorax in pediatric patients following cardiac surgery. The study found that a new treatment regimen, which included nil per oral, total parenteral nutrition, extended use of milrinone, and non-suction chest tube drainage, significantly reduced the occurrence of massive chylothorax. The research also noted a higher mortality rate in patients with chylothorax who developed acute kidney injury. The study concluded that the new treatment approach showed promise in reducing the frequency of chylothorax in post-cardiac surgical patients. [Extracted from the article]

A new report from the First Affiliated Hospital of Shandong First Medical University discusses the effectiveness and safety of different therapies for advanced heart failure. The researchers conducted a meta-analysis of 41 studies involving 5,137 patients and found that levosimendan had significant advantages over milrinone or dobutamine in reducing mortality and improving left ventricular ejection fraction (LVEF). However, the study also noted that hypotension events were more common in the levosimendan and milrinone groups. The research highlights the need for further studies due to the heterogeneity and small sample size of the existing evidence. [Extracted from the article]

A study conducted in Chengde, People's Republic of China, investigated the effects of combining esmolol and milrinone on cardiac function in septic shock patients. The study included 56 patients who were randomly divided into two groups: one receiving milrinone alone and the other receiving a combination of milrinone and esmolol. The results showed that the combination treatment significantly improved hemodynamics, reduced myocardial injury, and decreased inflammatory response compared to the group receiving milrinone alone. This research has been peer-reviewed and provides valuable insights into enhancing cardiac function in septic shock patients. [Extracted from the article]

A study conducted at Hainan Medical College in Haikou, People's Republic of China, investigated the efficacy of combining phentolamine and milrinone for the treatment of severe pneumonia in children. The study found that the co-administration of these drugs significantly reduced the levels of serum MMP-9, TIMP-1, and sICAM-1, and resulted in higher healing and therapeutic effectiveness compared to the control group. However, the researchers recommend conducting multi-center clinical trials before implementing this treatment in clinical practice. This information is published in the Tropical Journal of Pharmaceutical Research. [Extracted from the article]

A meta-analysis conducted by researchers at Southeast University in Nanjing, China, examined the effect of milrinone on adult critically ill patients. The study analyzed 20 randomized controlled trials involving 2,036 patients and compared milrinone with a control group. The results showed no significant difference in all-cause mortality or the incidence of myocardial infarction between the milrinone group and the control group. However, the incidence of ventricular arrhythmia decreased significantly in patients with cardiac surgery who used milrinone. The researchers concluded that more randomized controlled trials are needed to determine the reliable and conclusive evidence for milrinone's effects. [Extracted from the article]

A clinical trial, NCT06205758, is currently underway to evaluate the efficacy and safety of two drugs, levosimendan and milrinone, in the treatment of acute heart failure with or without renal dysfunction. The trial aims to develop a predictive modeling of the efficacy and safety of these drugs based on patient characteristics and renal function. The trial is recruiting participants and is expected to be completed by June 2025. The study is being conducted in China by Qianfoshan Hospital. [Extracted from the article]

A recent systematic review and meta-analysis conducted by the Department of Pediatrics in Sao Paulo, Brazil, evaluated the role of milrinone in the treatment of heart failure and pulmonary hypertension in neonates and children. The study included 41 relevant studies and found that milrinone significantly improved various cardiac parameters, such as left ventricular ejection fraction and cardiac index. However, it did not show significant improvements in other measures, such as ventricular myocardial performance index and ventricular longitudinal strain. The researchers concluded that further research is needed to better understand milrinone's mechanisms and refine its clinical applications in pediatric practice. [Extracted from the article]

A recent study conducted by researchers from the University of South Dakota explored the use of intraventricular milrinone for the treatment of severe vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH). Vasospasm is a serious complication of aSAH, and current management strategies are still debated among experts. The study reported a successful case of treating severe vasospasm with intraventricular milrinone in conjunction with standard therapy. The findings suggest that intraventricular milrinone may be an effective method for managing vasospasm in aSAH patients. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine examined the use of intravenous milrinone therapy in ambulatory patients with advanced heart failure. The study found that long-term use of milrinone was associated with improvements in cardiac index, New York Heart Association class, liver function, and tolerance of medical therapy. Additionally, patients who received milrinone for six months or longer experienced a decrease in hospitalization days and improved tolerance of beta blocker therapy. The findings suggest that long-term ambulatory intravenous milrinone therapy may be beneficial for patients with advanced heart failure. [Extracted from the article]

A study conducted by Ain Shams University in Cairo, Egypt, compared the efficacy of milrinone and sildenafil in treating persistent pulmonary hypertension of the newborn (PPHN). The study included 40 neonates with PPHN and found that both milrinone and sildenafil were effective and well-tolerated treatments. However, milrinone was found to be superior to sildenafil in improving oxygenation without lowering blood pressure parameters. The study suggests that milrinone and sildenafil can be viable alternatives for treating PPHN in areas where established therapies are not widely available. [Extracted from the article]

A meta-analysis conducted by researchers at the Children's Hospital of Nanjing Medical University evaluated the effects and safety of milrinone for the treatment of heart failure caused by severe pneumonia in children with congenital heart disease (CHD). The analysis included eight randomized controlled trials involving 680 CHD children. The results showed that milrinone was beneficial in improving clinical symptoms and cardiac function, with a higher total effective rate, shorter time to stable heart rate and respiration, and higher left ventricular ejection fraction compared to the control group. There was no significant difference in the incidence of adverse reactions between the milrinone group and the control group. However, more rigorous studies with larger sample sizes are needed to confirm these findings. [Extracted from the article]

A recent study conducted by researchers at the Arctic University of Norway (UiT) investigated the effects of different drugs on human cardiomyocytes during hypothermia. The study found that milrinone and isoprenaline increased the risk of ventricular arrhythmias during hypothermia, while levosimendan did not pose the same risk. Levosimendan was identified as a promising candidate for inotropic treatment of hypothermic patients due to its ability to treat hypothermia-induced cardiac dysfunction without increasing the risk of ventricular arrhythmias. This research provides valuable insights into potential treatment strategies for patients with accidental hypothermia. [Extracted from the article]

Keywords: Minneapolis; State:Minnesota; United States; North and Central America; Aminopyridines; Amrinone; Biomedicine; Cardiology; Cardiotonic; Cardiovascular Agents; Cell Transplantation; Cell Transplants; Connective Tissue Diseases and Conditions; Drugs and Therapies; Genetics; Health and Medicine; Hematology; Hematopoietic; Hurler Syndrome; Inborn Errors Carbohydrate Metabolism; Inotropic Agents; Lysosomal Storage Diseases and Conditions; Milrinone; Milrinone Therapy; Mucinoses; Mucopolysaccharidoses; Mucopolysaccharidosis I; Nutritional and Metabolic Diseases and Conditions; Pharmaceuticals; Risk and Prevention; Skin and Connective Tissue Diseases and Conditions; Stem Cell Transplants; Surgery; Transplant Medicine; Vasodilator Agents EN Minneapolis State:Minnesota United States North and Central America Aminopyridines Amrinone Biomedicine Cardiology Cardiotonic Cardiovascular Agents Cell Transplantation Cell Transplants Connective Tissue Diseases and Conditions Drugs and Therapies Genetics Health and Medicine Hematology Hematopoietic Hurler Syndrome Inborn Errors Carbohydrate Metabolism Inotropic Agents Lysosomal Storage Diseases and Conditions Milrinone Milrinone Therapy Mucinoses Mucopolysaccharidoses Mucopolysaccharidosis I Nutritional and Metabolic Diseases and Conditions Pharmaceuticals Risk and Prevention Skin and Connective Tissue Diseases and Conditions Stem Cell Transplants Surgery Transplant Medicine Vasodilator Agents 261 261 1 11/06/23 20231106 NES 231106 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in Nutritional and Metabolic Diseases and Conditions - Hurler Syndrome. [Extracted from the article]

Keywords: Kaohsiung City; Taiwan; Asia; Adrenergic beta-Antagonist; Amines; Aminopyridines; Amrinone; Antiarrhythmic Agents; Beta-Adrenergic Blocking Agents; Biogenic Monoamines; Cardiology; Cardiotonic; Cardiovascular Agents; Cardiovascular Physiological Phenomena; Cardiovascular Physiological Processes; Catecholamines; Drugs and Therapies; Enterovirus; Esmolol Therapy; Group II Antiarrhythmics; Health and Medicine; Hemodynamics; Inotropic Agents; Milrinone; Milrinone Therapy; Norepinephrine Therapy; Pharmaceuticals; RNA Viruses; Risk and Prevention; Vasodilator Agents; Vasopressors; Viral; Virology EN Kaohsiung City Taiwan Asia Adrenergic beta-Antagonist Amines Aminopyridines Amrinone Antiarrhythmic Agents Beta-Adrenergic Blocking Agents Biogenic Monoamines Cardiology Cardiotonic Cardiovascular Agents Cardiovascular Physiological Phenomena Cardiovascular Physiological Processes Catecholamines Drugs and Therapies Enterovirus Esmolol Therapy Group II Antiarrhythmics Health and Medicine Hemodynamics Inotropic Agents Milrinone Milrinone Therapy Norepinephrine Therapy Pharmaceuticals RNA Viruses Risk and Prevention Vasodilator Agents Vasopressors Viral Virology 1212 1212 1 10/30/23 20231103 NES 231103 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on RNA Viruses - Enterovirus have been presented. Kaohsiung City, Taiwan, Asia, Adrenergic beta-Antagonist, Amines, Aminopyridines, Amrinone, Antiarrhythmic Agents, Beta-Adrenergic Blocking Agents, Biogenic Monoamines, Cardiology, Cardiotonic, Cardiovascular Agents, Cardiovascular Physiological Processes, Catecholamines, Drugs and Therapies, Enterovirus, Esmolol Therapy, Cardiovascular Physiological Phenomena, Group II Antiarrhythmics, Health and Medicine, Hemodynamics, Inotropic Agents, Milrinone, Milrinone Therapy, Norepinephrine Therapy, Pharmaceuticals, RNA Viruses, Risk and Prevention, Vasodilator Agents, Vasopressors, Viral, Virology. [Extracted from the article]

Keywords: Aminopyridines; Amrinone; Brain Diseases and Conditions; Cardiovascular Diseases and Conditions; Central Nervous System Diseases and Conditions; Cerebrovascular Disorders; Health and Medicine; Hypertension; Intracranial Hemorrhages; Intracranial Vasospasm; Milrinone; Subarachnoid Hemorrhage EN Aminopyridines Amrinone Brain Diseases and Conditions Cardiovascular Diseases and Conditions Central Nervous System Diseases and Conditions Cerebrovascular Disorders Health and Medicine Hypertension Intracranial Hemorrhages Intracranial Vasospasm Milrinone Subarachnoid Hemorrhage 1080 1080 1 10/16/23 20231020 NES 231020 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Week -- Investigators discuss new findings in intracranial vasospasm. Keywords for this news article include: University Hospital Nantes, Amrinone, Milrinone, Hypertension, Aminopyridines, Health and Medicine, Intracranial Vasospasm, Subarachnoid Hemorrhage, Intracranial Hemorrhages, Cerebrovascular Disorders, Brain Diseases and Conditions, Cardiovascular Diseases and Conditions, Central Nervous System Diseases and Conditions. Aminopyridines, Amrinone, Brain Diseases and Conditions, Cardiovascular Diseases and Conditions, Central Nervous System Diseases and Conditions, Cerebrovascular Disorders, Health and Medicine, Hypertension, Intracranial Hemorrhages, Intracranial Vasospasm, Milrinone, Subarachnoid Hemorrhage. [Extracted from the article]

Keywords: Aminopyridines; Amrinone; Cardiovascular Diseases and Conditions; Glycerol; Health and Medicine; Hypertension; Lung Diseases and Conditions; Milrinone; Nitro Compounds; Nitroglycerin; Pulmonary Hypertension; Risk and Prevention; Sugar Alcohols EN Aminopyridines Amrinone Cardiovascular Diseases and Conditions Glycerol Health and Medicine Hypertension Lung Diseases and Conditions Milrinone Nitro Compounds Nitroglycerin Pulmonary Hypertension Risk and Prevention Sugar Alcohols 118 118 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- New research on pulmonary hypertension is the subject of a new report. For more information on this research see: Study of the Acute Hemodynamic Effects of Inhaled Milrinone versus Inhaled Nitroglycerin on Mechanically Ventilated Patients with Pulmonary Hypertension after Mitral Valve Replacement Surgeries. [Extracted from the article]

Birmingham, United Kingdom, Europe, Aminopyridines, Amrinone, Cardiology, Cardiomyopathies, Cardiotonic, Cardiovascular, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Dilated Cardiomyopathy, Drugs and Therapies, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Milrinone, Milrinone Therapy, Pediatrics, Pharmaceuticals, Vasodilator Agents Keywords: Birmingham; United Kingdom; Europe; Aminopyridines; Amrinone; Cardiology; Cardiomyopathies; Cardiotonic; Cardiovascular; Cardiovascular Agents; Cardiovascular Diseases and Conditions; Dilated Cardiomyopathy; Drugs and Therapies; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Heart Failure; Inotropic Agents; Milrinone; Milrinone Therapy; Pediatrics; Pharmaceuticals; Vasodilator Agents EN Birmingham United Kingdom Europe Aminopyridines Amrinone Cardiology Cardiomyopathies Cardiotonic Cardiovascular Cardiovascular Agents Cardiovascular Diseases and Conditions Dilated Cardiomyopathy Drugs and Therapies Health and Medicine Heart Disease Heart Disorders and Diseases Heart Failure Inotropic Agents Milrinone Milrinone Therapy Pediatrics Pharmaceuticals Vasodilator Agents 374 374 1 04/17/23 20230417 NES 230417 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Heart Disorders and Diseases - Dilated Cardiomyopathy. Keywords for this news article include: Birmingham, United Kingdom, Europe, Aminopyridines, Amrinone, Cardiology, Cardiomyopathies, Cardiotonic, Cardiovascular, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Dilated Cardiomyopathy, Drugs and Therapies, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Milrinone, Milrinone Therapy, Pediatrics, Pharmaceuticals, Vasodilator Agents, Department of Pediatric Cardiology. [Extracted from the article]

Aminopyridines, Amrinone, Cardiology, Cardiovascular Agents, Cardiotonic, Drugs and Therapies, Health and Medicine, Milrinone, Milrinone Therapy, Inotropic Agents, Pharmaceuticals, Pharmacodynamics, Pharmacokinetics, Pharmacology, Vasodilator Agents Keywords: Aminopyridines; Amrinone; Cardiology; Cardiotonic; Cardiovascular Agents; Drugs and Therapies; Health and Medicine; Inotropic Agents; Milrinone; Milrinone Therapy; Pharmaceuticals; Pharmacodynamics; Pharmacokinetics; Pharmacology; Vasodilator Agents EN Aminopyridines Amrinone Cardiology Cardiotonic Cardiovascular Agents Drugs and Therapies Health and Medicine Inotropic Agents Milrinone Milrinone Therapy Pharmaceuticals Pharmacodynamics Pharmacokinetics Pharmacology Vasodilator Agents 1048 1048 1 04/03/23 20230404 NES 230404 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Fresh data on milrinone therapy are presented in a new report. Keywords for this news article include: University of Montreal, Pharmaceuticals, Amrinone, Cardiology, Cardiotonic, Pharmacology, Aminopyridines, Inotropic Agents, Pharmacodynamics, Pharmacokinetics, Milrinone Therapy, Vasodilator Agents, Drugs and Therapies, Health and Medicine, Cardiovascular Agents. [Extracted from the article]

Keywords: Durham; State:North Carolina; United States; North and Central America; Aminopyridines; Amrinone; Arrhythmia; Cardiac Arrhythmias; Cardiac Surgery; Cardiology; Cardiotonic; Cardiovascular Agents; Drug Administration Routes; Drugs and Therapies; Health and Medicine; Heart Disorders and Diseases; Hospitals; Inotropic Agents; Intravenous Infusions; Kidney; Milrinone; Milrinone Therapy; Nephrology; Parenteral Infusions; Pharmaceuticals; Risk and Prevention; Vasodilator Agents EN Durham State:North Carolina United States North and Central America Aminopyridines Amrinone Arrhythmia Cardiac Arrhythmias Cardiac Surgery Cardiology Cardiotonic Cardiovascular Agents Drug Administration Routes Drugs and Therapies Health and Medicine Heart Disorders and Diseases Hospitals Inotropic Agents Intravenous Infusions Kidney Milrinone Milrinone Therapy Nephrology Parenteral Infusions Pharmaceuticals Risk and Prevention Vasodilator Agents 137 137 1 03/27/23 20230327 NES 230327 2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Researchers detail new data in Heart Disorders and Diseases - Cardiac Arrhythmias. Of the 197 patients who met inclusion, there was no difference in the presence of new arrhythmias (42.9% v 40.3%, p = 0.76) or in the time to first new arrhythmia from milrinone initiation in those with renal impairment compared to those without renal impairment (29.1 hours v 33.3 hours, p = 0.54). [Extracted from the article]

Keywords: Palo Alto; California; United States; North and Central America; Aminopyridines; Amrinone; Cardiology; Cardiotonic; Cardiovascular Agents; Cardiovascular Diseases and Conditions; Drugs and Therapies; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Heart Failure; Hospice Care; Inotropic Agents; Milrinone; Milrinone Therapy; Pediatrics; Pharmaceuticals; Terminal Care; Vasodilator Agents EN Palo Alto California United States North and Central America Aminopyridines Amrinone Cardiology Cardiotonic Cardiovascular Agents Cardiovascular Diseases and Conditions Drugs and Therapies Health and Medicine Heart Disease Heart Disorders and Diseases Heart Failure Hospice Care Inotropic Agents Milrinone Milrinone Therapy Pediatrics Pharmaceuticals Terminal Care Vasodilator Agents 2023 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Heart Disorders and Diseases - Heart Failure is the subject of a report. Treatment with vasoactive infusions at home may be a superior therapy for symptom control for these patients, rather than traditional pain and anxiety management with morphine and benzodiazepines." California, United States, North and Central America, Aminopyridines, Palo Alto, Amrinone, Cardiology, Cardiotonic, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Drugs and Therapies, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Hospice Care, Inotropic Agents, Milrinone, Milrinone Therapy, Pediatrics, Pharmaceuticals, Terminal Care, Vasodilator Agents. [Extracted from the article]

Aminopyridines, Amrinone, Angiology, Antiarrhythmic Agents, Brain Diseases and Conditions, Brain Injury, Brain Ischemia, Calcium Channel Blocking Agents, Cardiotonic, Cardiovascular Agents, Central Nervous System Diseases and Conditions, Craniocerebral Trauma, Drugs and Therapies, Group IV Antiarrhythmics, Health and Medicine, Inotropic Agents, Ischemia, Milrinone, Milrinone Therapy, Pharmaceuticals, Stenosis, Vascular Diseases and Conditions, Vasodilator Agents, Verapamil Therapy Keywords: Aminopyridines; Amrinone; Angiology; Antiarrhythmic Agents; Brain Diseases and Conditions; Brain Injury; Brain Ischemia; Calcium Channel Blocking Agents; Cardiotonic; Cardiovascular Agents; Central Nervous System Diseases and Conditions; Craniocerebral Trauma; Drugs and Therapies; Group IV Antiarrhythmics; Health and Medicine; Inotropic Agents; Ischemia; Milrinone; Milrinone Therapy; Pharmaceuticals; Stenosis; Vascular Diseases and Conditions; Vasodilator Agents; Verapamil Therapy EN Aminopyridines Amrinone Angiology Antiarrhythmic Agents Brain Diseases and Conditions Brain Injury Brain Ischemia Calcium Channel Blocking Agents Cardiotonic Cardiovascular Agents Central Nervous System Diseases and Conditions Craniocerebral Trauma Drugs and Therapies Group IV Antiarrhythmics Health and Medicine Inotropic Agents Ischemia Milrinone Milrinone Therapy Pharmaceuticals Stenosis Vascular Diseases and Conditions Vasodilator Agents Verapamil Therapy 2023 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators publish new report on brain ischemia. [Extracted from the article]